Why the study?
Warfarin is the standard of care and DOACs are newer drugs, prompting a comparison of their efficacy and safety for stroke prevention in patients with valvular heart disease.
Do direct oral anticoagulants reduce stroke or systemic embolism in patients with valvular heart disease compared to warfarin?
Population
Patients with valvular heart disease across five included studies
Comparison
DOACs vs warfarin
Design
Systematic review and meta-analysis
Authors
Loading...
DOACs may lower stroke risk versus warfarin in VHD; supports broader consideration but requires RCT confirmation.
Do direct oral anticoagulants reduce stroke or systemic embolism in patients with valvular heart disease compared to warfarin?
In patients with valvular heart disease, DOACs are associated with a significantly lower risk of stroke, systemic embolism, and major bleeding compared to warfarin.
Batool et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: